RxDoctor Payments Data

Harold Bernstein, MD

Glaucoma Specialist · Norfolk, VANPI 1215921994

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,876 of the $6,796 with a category attached, or 86.5%. It is spread thinly across 22 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations.

$6,796in general payments, 2019–2025

Across 147 payments — averaging $46.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$1K
  • Alcon$1K
  • AbbVie$1K
  • Glaukos Corporation$842
  • NEW World Medical,inc.$737
  • Sight Sciences, Inc.$244
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$82012%
  • Food & beverage$5,87686%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$203,127
Medicare patients
459
Services billed
2,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost155$78,477
CombiganBrimonidine Tartrate/Timolol38$15,084
Travoprost72$13,628
RhopressaNetarsudil Mesylate29$12,932
RocklatanNetarsudil Mesylat/Latanoprost29$12,267
SimbrinzaBrinzolamide/Brimonidine Tart41$12,131
Prednisolone Acetate224$8,648
Latanoprost807$7,542
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat414$6,653
VyzultaLatanoprostene Bunod21$6,425
Alphagan PBrimonidine Tartrate13$5,827
Brimonidine Tartrate227$5,586
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$4,533
Methazolamide21$3,633
Ketorolac Tromethamine82$3,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$1,233$99,388206 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$1,261$25,19958 claims
AlconSimbrinza$1,253$12,13141 claims
Bausch & Lomb Americas Inc.Vyzulta$153$6,42521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →